BioAtla (BCAB)

• Market cap: $45.2M
• 1 day: -2.94%
• 5 days: -6.81%
• 1 month: -33.72%
• 3 months: 23.62%
• 6 months: 91.53%
• Year to date: 25.21%
• 1 year: -35.39%
• 5 years: -97.61%
• 10 years: -97.52%
• Sector: Healthcare
• Industry: Biotechnology

About: BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.

Employees: 61